NCCN Guidelines for Patients® Version Updates: Non-Small Cell Lung Cancer Following are the major updates that were included in the NCCN Guidelines for Patients®: Non-Small Cell Lung Cancer, Version 1.2015 Part 2 – Assessing lung nodules More information has been added to explain how nodules are assessed for cancer. Page 15 Which types of doctors should be on your assessment team is explained. Page 21 Choices of how and when the nodule will be assessed for cancer are explained. Part 3 – Lung cancer staging Page 24 More information has been added to explain the staging plan for lung cancer. Part 4 – Treatment planning Page 33 The use of a PET/CT scan to find the best site to test for cancer that is spreading fast has been added. Page 38 Proteomic testing has been added. Part 5 – Overview of cancer treatments Page 49 New drugs to treat lung cancer have been added to the chart. Pages 50–51 Descriptions of new targeted therapy and immunotherapy drugs have been added. Part 6 – Treatment guide: One primary tumor Pages 60, 66, 76 LDCT (low-dose computed tomography) without contrast is recommended for the survivorship care plan if CT results are normal for two years. Pages 80–81 Ceritinib has been added as a second-line treatment for lung cancer with an ALK gene rearrangement. Pages 82–85 New drug treatments have been added for lung cancers with normal or unknown EGFR and ALK gene status. Page 83 An explanation of when proteomic testing can be used has been added. Part 7 – Treatment guide: Multiple primary tumors Pages 90, 92 LDCT (low-dose computed tomography) without contrast is recommended for the survivorship care plan if CT results are normal for two years.